Novel CAR-T for Glioblastoma Induced 'Dramatic' Responses in Early Trial

(MedPage Today) -- A new approach to chimeric antigen receptor (CAR) T-cell therapy showed promise in treating recurrent glioblastoma, according to a small phase I study. In the first-in-human trial, three patients with recurrent glioblastoma...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news